Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivo-MR2 in Primary CNS Lymphoma
NCT04609046Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2021
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide in primary central nervous system lymphoma (PCNSL), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 14 days and Proportion of evaluable patients who are able to stay on maintenance therapy at 6 months. Started May 2021; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04609046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609046.